Development of radioligands for in vivo imaging of type 1 cannbinoid receptors (CB1) in human brain

Current Pharmaceutical Design

Volumn 14, Issue 31, 2008, Pages 3363-3383

  Horti, Andrew G ^a   Van Laere, Koen ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE I 123; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE I 123; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE I 124; 1 (2,4 DICHLOROPHENYL) N (4 PHENYL) 4 METHYL 5 PHENYL 1H PYRAZOLE 3 CARBOXAMIDE F 18; 1 (5 FLUOROPENTYL) 1H INDOL 3 YL) (2 IODOPHENYL)METHANONE F 18; 1 (5 FLUOROPENTYL) 4 METHYL 5 PHENYL N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE F 18; 2 IODOPHENYL 1 (N METHYLPIPERIDIN 2 YLMETHYL)INDOLE I 131; 3 (4 FLUORONAPHTHOYL) 1 (N METHYLPIPERIDIN 2 YLMETHYL)INDOLE F 18; 4 CYANO 1 (2,4 DICHLOROPHENYL) 5 (4 METHOXYPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE C 11; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; DRONABINOL; FLUORODRONABINOL F 18; N (PIPERIDIN 1 YL) 5 (4 METHOXYPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE C 11; NABILONE; PLACEBO; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; RIMONABANT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; LIGAND;

BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN REGION; CATALEPSY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ANALYSIS; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPOTHERMIA; IN VIVO STUDY; LIGAND BINDING; LIPOPHILICITY; LOCOMOTION; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NON INVASIVE PROCEDURE; NONHUMAN; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; RADIOASSAY; SCINTISCANNING;

BRAIN; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1;

EID: 59649092456     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786549380     Document Type: Review

References (115)

1. Mechoulam R. Interview with prof. Raphael Mechoulam, codiscoverer of THC. Interview by Stanley Einstein. Int J Addict 1986; 21: 579-87.
2. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93: 217-24.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
5. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
6. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279 (Pt 1): 129-34.
7. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005; 83: 944-54.
8. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
9. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23.
10. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575.
11. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-84.
12. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008; 11: 152-9
13. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
14. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007; 9: 413-30.
15. Van Laere K. In vivo imaging of the endocannabinoid system: A novel window to a central modulatory mechanism in humans. Eur J Nucl Med Mol Imaging 2007; 34: 1719-26.
16. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-34.
17. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
18. Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 study group. Division of aids treatment research initiative. AIDS Res Hum Retroviruses 1997; 13: 305-15.
19. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619-31.
20. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: The hash realities. Nat Rev Neurosci 2007; 8: 885-95.
21. Hertzog DL. Recent advances in the cannabinoids. Expert Opin Ther Pat 2004; 14: 1435-1452.
22. Gambi F, De Berardis D, Sepede G, Quartesan R, Calcagni E, Salerno RM, et al. Cannabinoid receptors and their relationships with neuropsychiatric disorders. Int J Immunopathol Pharmacol 2005; 18: 15-9.
23. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: Cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004; 96: 376-81.
24. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716a binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 355-60.
25. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3h]cp-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schιzophrenia and cannabis use. Neuroscience 2001; 103: 9-15.
26. Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl) 1999; 144: 144-50.
27. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol Life Sci 2006; 63: 1597-613.
28. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003; 27: 289-301.
29. Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005; 6: 215-23.
30. Smith RA, Fathi Z. Recent advances in the research and development of CB(1) antagonists. IDrugs 2005; 8: 53-66.
31. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, et al. The acyclic CB1r inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7: 68-78.
32. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716a, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
33. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrin Metab 2007; 18: 27-37.
34. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. Sr 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
35. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005; 312: 875-83.
36. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist sr141716. Arch Gen Psychiatry 2001; 58: 322-8.
37. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, et al. Cannabinoid receptor 1 blocker rimonabant (SR141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008; 28: 317-24.
38. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007; (4): CD005353.
39. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Metaanalysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23: 17-24.
40. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007; 150: 519-25.
41. Bifulco M, Laezza C, Malfitano AM. From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Mult Scler 2007; 13: 133-4.
42. Hohmann AG, Suplita RL, 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J 2006; 8: E693-708.
43. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
44. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004; 16: 159-72.
45. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
46. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: A regional and laminar analysis. Cereb Cortex 2007; 17: 175-91.
47. Grimsey NL, Goodfellow CE, Scotter EL, Dowie MJ, Glass M, Graham ES. Specific detection of CB(1) receptors; cannabinoid CB(1) receptor antibodies are not all created equal! J Neurosci Methods 2008; 171: 78-86.
48. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human pet brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007; 104: 9800-5
49. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83: 349-53.
50. Wand GS, Oswald LM, McCaul ME, Wong DF, Johnson E, Zhou Y, et al. Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology 2007; 32: 2310-20.
51. Morris ED, Yoder KK. Positron emission tomography displacement sensitivity: Predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics. J Cereb Blood Flow Metab 2007; 27: 606-17.
52. Terry G, Liow JS, Chernet E, Zoghbi SS, Phebus L, Felder CC, et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB(1) receptors in rodents. Neuroimage 2008; 41: 690-8.
53. Eckelman WC, Reba RC, Gibson RE. Receptor-binding radiotracers: A class of potential radiopharmaceuticals. J Nucl Med 1979; 20: 350-357.
54. Lee CM, Farde L. Using positron emission tomography to facilitate cns drug development. Trends Pharmacol Sci 2006; 27: 310-6.
55. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003; 5: 363-75.
56. Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123I-labeled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 1996; 307: 331-8.
57. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, et al Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR141716a. J Biol Chem 1996; 271: 6941-6.
58. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, et al. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 2003; 46: 5139-52.
59. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-7.
60. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16: 89-97.
61. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of gdp/gtp exchange. J Neurochem 1999; 72: 2379-87.
62. Charalambous A, Marciniak G, Shiue CY, Dewey SL, Schlyer DJ, Wolf AP, et al. Pet studies in the primate brain and biodistribution in mice using (-)-5′-18F-delta-8-THC. Pharmacol Biochem Behav 1991; 40: 503-7.
63. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: Development of a radio-ligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 1998; 70: 417-23.
64. Bonhomme-Faivre L, Benyamina A, Reynaud M, Farinotti R, Abbara C. Disposition of delta(9) tetrahydrocannabinol in CF1 mice deficient in MDR1a p-glycoprotein. Addict Biol 2008; (In press).
65. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999; 42: 769-76.
66. Lan R, Gatley SJ, Makriyannis A. Preparation of iodine-123 labeled AM251: A potential spect radioligand for the brain cannabinoid CB1 receptor 1996; 38: 875-881.
67. Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem 2003; 46: 642-5.
68. Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E. Modulation of p-glycoprotein activity by cannabinoid molecules in hk-2 renal cells. Br J Pharmacol 2006; 148: 682-7.
69. 123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 2004; 55: 904-15.
70. 124I]AM281 pet demonstrated in a schizophrenic patient. Psychiatry Res 2006; 147: 249-56.
71. Gatley SJ, Gifford AN, Ding Y-S, Volkow ND, Lan R, Liu Q, et al. Development of PET and SPECT radioligands for cannabinoid receptors. Drug Discov Strat Method 2004; 24: 129-46.
72. 18F]AM5144 and related pyrazole compounds. Nucl Med Biol 2005; 32: 361-6.
73. Gatley SJ. Progress towards the development of a pet radioligand for cannabinoid CB1 receptors. Neuropsychopharmacology 2005; 30, Suppl 1: S65.
74. 18F]SR144385: A selective radioligand for positron emission tomographic studies of brain cannabinoid receptors. J Labelled Compd Rad 1999; 42: 589-96.
75. 18F]SR147963: Selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl Med Biol 2000; 27: 757-62.
76. Mathews WB, Scheffel U, Rauseo PA, Ravert HT, Frank RA, Ellames GJ, et al. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nucl Med Biol 2002; 29: 671-7.
77. Katoch-Rouse R, Chefer SI, Pavlova OA, Vaupel DB, Matochik JA, Caulder T, et al. Development of PET radioligands for imaging of CB1 receptor. In: IX Symposium on the Medical Applications of Cyclotrons; 2002: Turku, Finland: Turku University; 2002. p.136.
78. 18F]fluorination: A PET radiotracer for studying CB1 cannabinoid receptors. J Labelled Compd Rad 2003; 46: 93-7.
79. 11C]1-(2-chlorophenyl)- 5-(4-methoxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide: A potential PET ligand for CB1 receptors. Bioorg Med Chem Lett 2004; 14: 2393-6.
80. 18F-labeled analog of O-1302 for use in cerebral CB1 cannabinoid receptor imaging. Biol Pharm Bull 2008; 31: 1274-8.
81. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: Selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 1993; 264: 1352-63.
82. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, et al. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995, 38: 3094-105.
83. Huffman JW, Padgett LW. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 20051; 12: 1395-411.
84. Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, et al. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CBI cannabinoid receptor. J Med Chem 2005; 48: 6386-92.
85. Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem 2005; 48: 5813-22.
86. Makriyannis A, Deng H. Preparation of cannabimimetic indole derivatives with cannabinoid CB1 or CB2 receptor binding affinity. International patent application 2001; WO 01/28557
87. Willis PG, Katoch-Rouse R, Horti AG. Regioselective F-18 radio-labeling of AM694, a CB1 cannabinoid receptor ligand. J Labelled Compd Rad 2003; 46: 799.
88. Tamagnan G, Lu XJ, Gao Y, Amici LA, Baldwin RM, Innis RB. Potential SPECT radioligand for cannabinoid receptor. J Labelled Compd Rad 1999; 43: S191-S193.
89. Hord AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, et al. 11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 2006; 47: 1689-96.
90. 11C]JHU75575) as potential radioligands for pet imaging of cerebral cannabinoid receptor. J Labelled Compd Rad 2006; 49: 1021-36.
91. Fan H, Kotsikorou E, Hoffman A, Ravert H, Holt D, Hurst D, et al. Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity. Eur J Med Chem. [publication on the internet ahead of print] 2008; available from: Http://www.elsevier.com/locate/ejmech.
92. 11C]JHU75528, a PET radioligand for imaging of cerebral cannabinoid CB1 receptors. [published on the internet] Neural Plast 2007 [cited 09/ 24/2007]; available from: DOI: 10.1155/2007/23250.
93. 11C]OMAR. J Nucl Med 2008; 49 (Suppl 1): 131P.
94. Lin LS, Lanza TJ, Jr., Jewell JP, Liu P, Shah SK, Qi H, et al. Discovery of n-(1S,2S)-3-(4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl) pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006; 49: 7584-7.
95. Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, et al. Conformational analysis and receptor docking of n-(1S,2S)-3-(4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl- 2-{[5-(trifluoromediyl)pyridin- 2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J Med Chem 2008; 51: 2108-14.
96. 18F]fluoroethoxy) phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin- 2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use. J Med Chem 2007; 50: 3427-30.
97. Van Laere K, Goffin K, Casteels C, Dupont P, de Hoon J, Bormans G. In vivo PET mapping of the human cerebral cannabinoid-type 1 receptor: age- and gender dependence. Neuroimage 2008; 39: 1533-41.
98. Van Laere K, Koole M, Sanabria Bohorquez SM, Goffin K, Guenther I, Belanger MJ, et al. Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects. J Nucl Med 2008; 49: 439-45.
99. 11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB(1) receptors in nonhuman primate brain. Neuropsychopharmacology 2008; 33: 259-69
100. Allen JR, Amegadzie AK, Gardinier KM, Gregory GS, Hitchcock SA, Hoogestraat PJ, et al. Preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators. International patent application 2005; WO2005066126
101. Donohue S, Halldin C, Schou M, Hong J, Phebus L, Chernet E, et al. Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluoro-benzyl)4-(3- (piperidin-1-yl)-indole- 1-sulfonyl) benzamide (pipisb), with carbon-11 or fluorine-18. J Labelled Compd Rad 2008; 51: 146-52.
102. 2 receptors in human brain. Curr Pharm Des 2003; 9: 673-96.
103. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003; 8: 927-33.
104. Hansch C, Steward AR, Anderson SM, Bentley D. The parabolid dependence of drug action upon lipophilic character as revealed by a study of hypnotics. J Med Chem 1968; 11: 1-11.
105. Kubinyi H. 3-D structure-activity relationships. In: Manfred EW, editor. Burger's medicinal chemistry and drug discovery, 5th ed. New York: Wiley; 1995, p. 497-571.
106. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003; 5: 376-89.
107. Welch MJ, Chi DY, Mathias CJ, Kilbourn MR, Brodack JW, Katzenellenbogen JA. Biodistribution of n-alkyl and n-fluoroalkyl derivatives of spiroperidol; radiopharmaceuticals for pet studies of dopamine receptors. Nucl Med Biol 1986; 13: 523-7.
108. Kessler RM, Ansari MS, de Paulis T, Schmidt DE, Clanton JA, Smith HE, et al. High affinity dopamine d2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med 1991; 32: 1593-600.
109. 11C]CB-119, PET tracers for the cannabinoid CB1 receptor. J Labelled Compd Rad 2007; 50: S73.
110. Van Laere K, Goffin K, Casteels C, Mortelmans L, de Hoon J, Bormans G, et al. In vivo PET of cerebral cannabinoid-1 receptor availability is inversely correlaied to novelty seeking in healthy human volunteers. J Nucl Med 2008; 49 (Suppl. 1): 372P.
111. Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A. Effect of the cannabinoid receptor spect agent, am 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997; 238: 84-6.
112. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK, et al. Synthesis, ex vivo evaluation and radiolabeling of potent 1,5-diphenyl-pyprolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem 2008; 51:5833-42.
113. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008; 14(23): 2279-88.
114. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008; 14(23): 2347-61.
115. Pazos MR, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008; 14(23): 2317-25.